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Introduction
Efficient signal transmission from the motor neuron to a skeletal muscle fiber at the neuromuscular junction (NMJ) is a prerequisite for muscle contraction 1 . When an action potential reaches the presynaptic button, the neurotransmitter acetylcholine (ACh) is released into the synaptic cleft. Binding of ACh to nicotinic acetylcholine receptors (AChR) at the motor end plate of the muscle fiber induces opening of the cation selective ion channels leading to depolarisation of the muscle fiber, the release of calcium ions from the sarcoplasmic reticulum, and ultimately muscle contraction. A number of different neurological conditions can result from impaired neuromuscular transmission varying from poisoning with botulinum and snake venom toxins, through the autoimmune mediated NMJ disorders such as myasthenia gravis and the Lambert-Eaton myasthenic syndrome, to the hereditary congenital myasthenic syndromes (CMS, for a discussion of genetic heterogeneity of CMS, see [MIM 608931]) 2, 3 . These conditions may lead to generalized paralysis and respiratory failure and if untreated can be life-threatening. The neuromuscular junction is probably the most studied synapse but many aspects of its formation, maturation, stabilization, and functional efficacy remain incompletely understood 4 .
During the last two decades, research into the molecular causes of CMS has led to the identification of mutations in several genes and has greatly influenced established or inferred concepts of NMJ pathophysiology 3 . Here we used positional cloning to determine the underlying defect in a rare autosomal recessive CMS that is characterized by a limb-girdle pattern of muscle weakness combined with the presence of tubular aggregates on muscle biopsies (Myasthenia, limb-girdle, with tubular aggregates [MIM 610542]) 5, 6 . Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles (Figure 1 ), sparing of ocular or facial muscles, neurophysiologic signs of NMJ dysfunction (decrement of the muscle action potential with repetitive nerve stimulation), and a good treatment response to acetylcholinesterase (AChE) inhibitors. Genetic evaluation of these families revealed pedigrees typical of an autosomal recessive trait but the underlying genetic defect had not yet been identified. We localised and refined the genetic interval on chromosome 2 by homozygosity mapping, identified mutations in the gene encoding glutaminefructose-6-phosphate transaminase 1 (GFPT1) as a so-far unrecognized cause of CMS and recapitulated human pathology in zebrafish morphants. GFPT1 catalyzes the transfer of an amino group from glutamine onto fructose-6-phosphate, yielding glucosamine-6-phosphate (GlcN-6-P) and glutamate. This transamidase reaction has been identified as the first and rate-limiting step of the hexosamine biosynthesis pathway, which is the obligatory source of essential amino sugars for the synthesis of glycoproteins, -lipids, and proteoglycans (Figure S1) 7 . As many key NMJ proteins are glycosylated 8 our data will pave the way for new studies on the functional integrity of the neuromuscular synapse.
Materials and Methods

Patients
Pedigrees and countries of origin of 16 CMS families are shown in Figure S2 and a synopsis of clinical findings is shown in Figure 1 . Five families, LGM3, LGM4,
LGM13, LGM15 and LGM16, have been published earlier 9, 10 . Venous blood samples were obtained from the patients as well as from their unaffected parents and siblings.
Genomic DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega, Mannheim, Germany) according to the manufacturer's recommendations. (Table S1 ). We ranked the annotated sequences with respect to neuromuscular junction and skeletal muscle biology and disease. We used information from public databases and characterized proteins in silico by BLAST alignments to protein database entries and comparison of domain composition and organization with the SMART algorithm. We also investigated positional candidate genes for structural and functional homology with the known proteins involved in CMS and related disorders. Sixteen genes were screened for mutations (Table S1 ). Primer pairs for each exon including flanking intron sequences were designed from genomic sequence using Primer3 (for GFPT1: genomic DNA AC114772 . Video recordings of embryos and larvae and light microscopy images were taken using a Leica dissection stereomicroscope equipped with a Moticam 1000 camera (Leica, Wetzlar, Germany). Touch-evoked swimming response was elicited by touching the head or the tail of the embryos with a pipette tip.
Antisense morpholino oligonucleotide knockdown
Antisense morpholino oligonucleotides (MOs) were purchased from Gene Tools (Pilomath, OR). The MOs were designed using the mRNA sequence of the zebrafish GFPT1 orthologue gfpt1 and genomic sequences available from public databases . Three independent MO injection experiments were performed for each MO and at least 500 injected embryos were evaluated in total for each MO.
RNA isolation and RT-PCR
RNA from zebrafish embryos and human cultured myoblasts, myotubes or muscle biopsies was isolated with Trizol reagent (Invitrogen) following the manufacturer's instructions. Reverse transcription was performed with 1 or 2 ȝg total RNA as template using the Superscript III First-Strand Synthesis System (Invitrogen).
Regions of interest in the GFPT1 and gfpt1 cDNA were amplified with suitable primer sets. For segregation analysis in families, PCR products from patients' cDNA containing GFPT1 mutations were subcloned into the pGEM-T Easy vector (Promega) and individual clones were isolated and sequenced.
Immunofluorescence stainings
For immunofluorescence analysis, cells were grown on glass coverslips and transfected as described above. Forty-eight hours after transfection, coverslips were washed in PBS, fixed in 3.7% formaldehyde in 1x CSK buffer (100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 10 mM PIPES; pH 6.8) for 10 min at room temperature, and permeabilized with 0.1% Triton X-100 in 1x CSK buffer for 15 min. 
Statistical analysis
The data show the mean ± SD. Statistical significance was determined using a twotailed Student's t test. Significance was set at P < 0.05 (one asterisk), P < 0.01 (two asterisks), or P < 0.001 (three asterisks).
Results
We had access to eleven so far unreported and two previously reported families with LGM8, LGM10, LGM11, LGM12; Figure S2 ). Although these pedigrees were too small to give significant LOD scores, reconstruction of haplotypes was in full agreement with linkage to this locus. We systematically exploited the genotyping data to detect potential recombination events. Under the assumption of genetic homogeneity, historic recombination events suggested from regions of homozygosity in families LGM10 and LGM11 narrowed the critical genetic interval to a region of interest of 5.92 Mb ( Figure S3 ).
We evaluated and ranked the 46 genes in this region (Table S1 ) on the basis of expression pattern and function, and sequenced the entire coding region and exonintron boundaries of 16 genes in the index cases from the three families that produced the highest LOD scores (LGM1, LGM3 and LGM10). We identified different homozygous missense mutations in the gene encoding glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in these three families ( Figure 2 ) and no disease-related changes in any of the other sequenced genes. We obtained further evidence for a causative role of GFPT1 mutations when extending GFPT1 mutation screening to the remaining 13 families, yielding biallelic mutations in all pedigrees except for families LGM4, LGM15 and LGM16 ( Figure S4 ). We identified a total of 18 different GFPT1 mutations consisting of 13 missense mutations, three frameshift mutations, one nonsense mutation and one variant in the 3'-UTR ( Figure 2 , Table 1 ).
When DNA from family members was available, we observed that the disease cosegregated with recessive inheritance of the GFPT1 mutations. The parents carried mutations in the heterozygous state, and unaffected siblings carried either one heterozygous mutation or were homozygous for the wild type alleles. When DNA from family members was not available (families LGM9 and LGM13), subcloning and sequencing of amplicons from cDNA derived from muscle biopsies demonstrated that the mutations were on separate alleles. We observed that some GFPT1 missense mutations caused rather mild amino acid changes or affected residues that are not strictly conserved in orthologues (Table 1, Figure S5 ). Nevertheless, analysis of extended numbers of healthy control individuals, adjusted to the type of mutation (at least 103 for each truncating and 221 for each missense mutation; 635 for the 3'-UTR variant), did not yield any of the identified genotypes (Table 1) .
We noted that the crystal structures of the E. coli orthologue for GFPT1 (GlmS) and of the isomerase domain of human GFPT1 had been solved (Protein Data Bank
[PDB] accession numbers 2J6H and 2ZJ3) 25, 26 . Using this data as the basis of a structural model for human GFPT1, the c.1154G>A (p.Arg385His) mutation would be predicted to impair GFPT1 function, since the arginine residue at position 385 in human GFPT1 corresponds to E. coli GFPT1 arginine 312 which contributes to the GFPT1 dimer interface. Other GFPT1 missense mutations do not affect amino acid residues required for oligomerisation or involved in the catalytic mechanism.
Consistent with this observation heterologous protein expression of the GFPT1 mutants p.Thr15Ala, p.Asp43Val and p.Asp348Tyr had only small effects on enzymatic activity and of the mutants p.Arg111Cys and p.Arg434His no effect at all ( Figure S6 ). We also did not observe any major effect of the GFPT1 mutations on subcellular localization of the protein in transfected cells ( Figure S6 ). By contrast, we found substantially reduced GFPT1 levels in muscle biopsies ( Figure 2 ) and cultured primary myoblasts and myotubes obtained from GFPT1 patients ( Figure S6 ).
Reduced amounts of GFPT1 were also seen in patients with the 3'-UTR mutation c.*22C>A (LGM5.5, LGM9.3).
We also set up experiments to follow potential indirect or direct functional consequences of GFPT1 mutations. Radiometric assays showed a strongly reduced number of AchR available for 125 I-Į-bungarotoxin binding at motor end-plates of GFPT1 patient LGM8.3 (to around 25% of normal). The end product of the hexosamine pathway, uridine diphospho-N-acetylglucosamine (UDP-GlcNAc), is involved in multiple glycosylation processes 7 including the dynamic modification of serine or threonine residues of intracellular proteins (O-GlcNacylation) 27 ( Figure S1 ).
We therefore immunoblotted muscle samples of GFPT1 patients and controls with the RL2 antibody, which selectively detects O-GlcNAc residues on numerous proteins 28 . As expected, the antibody recognized several bands whose intensities were markedly decreased in muscles from GFPT1 patients (Figure 2 ).
In a final series of experiments, we used zebrafish as an animal model. GFPT1 is conserved in zebrafish, with high expression levels during early somite development (data not shown). We knocked down the expression of the zebrafish GFPT1 orthologue gfpt1 by injection of antisense morpholino oligonucleotides (MOs), a translation-blocking MO targeting the region surrounding the start codon (MO1) and a splice-blocking MO targeting the splice donor site of intron 5 (MO2). Both MOs induced a clear reduction of gfpt1 levels at 48 hours post fertilization (hpf) ( Figure   S7 ). Knockdown of neuromuscular junction proteins usually affects motility and swimming behaviour of injected embryos. Indeed, MO-injected embryos displayed altered tail morphology (curled tails and shortened tails, Figure 3) , and swimming and touch-evoked escape response at 48 hpf were severely impaired (Video S1).
Histologically, we observed abnormal muscle morphology and delayed NMJ development. Somites had lost their regular chevron-shape with rounding of myosepta to a C-shape instead of the V-shape in control embryos. Staining for slowtwitch muscle fibers revealed morphological abnormalities ranging from wavy fibers to severely damaged fibers that were detached from the vertical myoseptum ( Figure   3 ). NMJ development progressed normally up to 24 hpf, but from 24 hpf onwards, NMJ development was delayed. Motor neuron axons had completely or partially lost their ability to project branches into laterally located muscle fibers and to form synapses with them ( Figure 3 ). Both MOs resulted in strikingly similar phenotypes while embryos injected with a standard control MO were indistinguishable from noninjected embryos (data not shown).
Discussion
In this study we provide twofold genetic evidence that GFPT1, the key enzyme of the hexosamine pathway yielding essential amino sugars for carbohydrate modifications, is required for critical events in neuromuscular transmission. Specifically, we localized and refined the genetic interval for a so far genetically undetermined autosomal recessive CMS on chromosome 2 and identified GFPT1 mutations as the molecular defect. This finding was recapitulated by a neuromuscular morphant phenotype observed in zebrafish embryos lacking GFPT1. We found 18 different homozygous and compound heterozygous GFPT1 mutations in 13 unrelated families, and GFPT1 mutations occurred in CMS cohorts of various ethnic origins.
Although failure to detect mutations in three additional cases is probably related to so-far unexplored mutation mechanisms or involvement of additional unknown genes, our data indicates that GFPT1 mutations represent the major cause for limbgirdle CMS with good treatment response to AChE inhibitors or tubular aggregates in muscle biopsies. With respect to genetic diagnosis and counselling, limb-girdle CMS patients with effective response to AChE inhibitors or tubular aggregates in muscle biopsies should undergo GFPT1 sequencing while all other limb-girdle CMS patients should be screened for DOK7 mutations first and -if negative -for GFPT1 mutations.
In metazoa, there are two GFPT genes, GFPT1 and GFPT2, encoding isozymes with different tissue distributions 29 . GFPTs are homodimeric, cytoplasmic enzymes that transfer an amino group from glutamine onto fructose-6-phosphate, yielding glucosamine-6-phosphate (GlcN-6-P) and glutamate. This reaction is the first and rate-limiting step of the hexosamine biosynthesis pathway ( Figure S1 ), which is the obligatory source of essential building blocks for the glycosylation of proteins and lipids 7 . GFPT1 is the only or predominant isoform in kidney, pancreas and liver.
Since glycosylation is essential for cell survival it might be expected that GFPT1 mutations create hypomorphic alleles. Indeed none of our patients carries two null mutations in the constitutive exons of the GFPT1 gene. The homozygous p.Trp240X mutation (family LGM2) is predicted to lead to decreased GFPT1 levels only in heart and skeletal muscle as it occurs in an alternative 18-amino-acid exon, exclusively incorporated in the predominant GFPT1 species in striated muscle 16 . The expected residual function of GFPT1 mutants is also consistent with our finding that some GFPT1 missense mutations result in amino acids with similar physicochemical properties or affect residues that are not strictly conserved in orthologues ( Figure   S5 ).
With the notable exception of p.Arg385His, which potentially affects GFPT1 dimerisation, in silico structural modelling and heterologous expression studies did not reveal definite pathophysiological effects of GFPT1 mutants. However, protein expression data in patients' muscle cells and biopsy specimens suggest that GFPT1 mutations may lead to substantially reduced GFPT1 levels. The mechanism by which the mutants inhibit protein expression remains to be determined but may involve reduced levels of GFPT1 mRNA, increased GFPT1 turn-over, or interference with protein translation. Notably, the 3'-UTR mutation c.*22C>A (patients LGM5.5,
LGM9.3) was also associated with reduced amounts of GFPT1. For this particular mutation the combination of an observed decrease in protein levels, its presence in three unrelated families, its absence in a large number of control chromosomes, and compound heterozygosity with a truncating mutation in one family strongly suggests that c.*22C>A is a disease-causing variant. Nevertheless, the pathogenic mechanism at the molecular level of c.*22C>A is not yet clear. Analysis of the GFPT1 skeletal muscle mRNA by RT-PCR in two patients excluded effects on splicing and showed similar levels of wild-type and mutated position c.*22 mRNA expression ( Figure S6 ).
It is possible that this mutation, like many 3'-UTR mutations in other genes, affects translational efficiency 30 .
Other CMS related genes known to date encode structural components of the neuromuscular junction while GFPT1 is believed to play a more general role in the cell. The product of the transamidase reaction catalyzed by GFPT1, GlcN-6-P, is used in the hexosamine pathway to synthesize uridine diphospho-Nacetylglucosamine (UDP-GlcNAc) that serves as common precursor for all amino sugars used for the synthesis of glycoproteins, -lipids, and proteoglycans ( Figure S1 Identification of such changes may also help to clarify why, while universally required, the functions of the NMJ is especially vulnerable to alterations of the hexosamine pathway.
In order to obtain further proof that a reduction of GFPT1 levels leads to NMJ or muscle dysfunction we utilized zebrafish as an animal model. Although overall the muscle structure of zebrafish differs from mammalian muscles 
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Figures S1 to S7 Table S1 Legend to Video S1 Missense mutations identified in CMS patients are indicated above the alignments.
The corresponding regions of eleven different organisms were aligned by using the ClustalW algorithm. Note that not all mutations target highly conserved residues. In the case of the p.Met491Thr mutation there is even a threonine already present at this position in the C. elegans sequence. On the other hand, the micro environment of this residue which points into the inner part of the molecule (PDB accession number 2V4M for human GFPT1 isomerase domain) is supposed to be different and, thus, may cause a disadvantage of the hydrophilic threonine residue over the hydrophobic methionine in the human GFPT1 structure. Similarly, the GFPT1 mutation p.Arg512Trp is in a region which is conserved in the closely related mammals (e.g., pig and mouse). In other organisms, this position is exchanged by residues smaller than arginine, suggesting that the bulky tryptophane in this position may produce sterical hindrance. Note that embryos at different stages of development express different levels of actin as displayed in the lower panel.
